Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos

Inward Investment
Return to: PBR Home | Inward Investment

Inward Investment

New WuXi Life Science to acquire WuXi PharmaTech for $3.3bn Shanghai-based WuXi PharmaTech has entered into a merger agreement with New WuXi Life Science and its wholly owned subsidiary WuXi Merger, worth a total cash consideration of $3.3bn.
Inward Investment > News
PPF Group acquires minority stake in Cytune Pharma By PBR Staff Writer
PPF Group, in cooperation with SOTIO has completed acquisition of minority stake in French biotechnology firm Cytune Pharma.
Inward Investment > News Merck in talks to acquire Cubist Pharmaceuticals for nearly $8bn By PBR Staff Writer
New Jersey-based drug giant Merck & Co is, reportedly, in talks over a potential acquisition of antibiotics maker Cubist Pharmaceuticals for more than $8bn.
Inward Investment > News
See more Inward Investment news

Latest Inward Investment News and Insight

View all Inward Investment news or find news targeted to your interests
Truly Parallel - Cell Culture
| By Eppendorf
DASGIP® Bioreactor Systems for Cell Culture Applications.
Inward Investment > White Papers
Product Brochure: Most Compact
| By Eppendorf
DASbox® Mini Bioreactor System for Cell Culture and Microbiology.
Inward Investment > White Papers
Evaluation of the BioFlo® 320 Process Capabilities
| By Eppendorf
This poster characterizes the capabilities of the BioFlo320 in terms of key process parameters including oxygen transfer rate (OTR), volumetric mass transfer coecient (kLa), tip speed, mixing time, and water consumption. These data enable quantitative analyses of bioprocess engineering parameters, thus allowing potential users to gain insight into the system’s cell culture and fermentation capabilities.
Inward Investment > White Papers
Taking the Strain
| By Eppendorf
Today, the rapidly expanding demand for vaccine products for viral diseases such as rabies has necessitated the development of more sophisticated production techniques based around cell culture systems. This article reviews vaccine production strategies, with a focus on rabies, looking specifically at the use of the Vero cell line - used worldwide and approved by the US Food and Drug Administration - as well as media technology and the bioreactor options available.
Inward Investment > White Papers
DASGIP® Control is now DASware® control 5 - Parallel Processing Advances Bioprocess Development
With DASware control 5 Eppendorf presents its revised software for benchtop bioprocess control. The updated graphical user interface provides intuitive process views, user-defined functions, and configurable charts.
Inward Investment > Press Releases
Growing Potential: mAb Production With Fibra-Cel
| By Eppendorf
The market for monoclonal antibodies continues to grow steadily, but there are still bottlenecks in the development of new products, including long development times mostly due to R&D. Advanced bioprocess equipment that meets the specific demands of mAb-producing hybridoma can accelerate design and production, and reduce overall development costs along the way.
Inward Investment > White Papers
DoE Bioprocess Development
| By Eppendorf
Eppendorf DASware is the effective route to design of experiments (DoE) in early-stage bioprocess development. Claudia M Huether-Franken and Sebastian Kleebank explain how the design software applies DoE to DASGIP parallel bioreactor systems.
Inward Investment > White Papers
Eppendorf and Florida State University Collaboration Demonstrates Large-Scale Stem Cell Expansion
A collaboration between Eppendorf and Florida State University has successfully shown the feasibility of large-scale expansion of human mesenchymal stem cells (MSC) using the company's proprietary Fibra-Cel® packed-bed technology.
Inward Investment > Press Releases
PPF Group acquires minority stake in Cytune Pharma
By PBR Staff Writer
PPF Group, in cooperation with SOTIO has completed acquisition of minority stake in French biotechnology firm Cytune Pharma.
Inward Investment > News
View all Inward Investment news or find news targeted to your interests